Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2017

Publisher Name :
Date: 30-May-2017
No. of pages: 31

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Nitric oxide synthase 1 or NOS1 is an enzyme encoded by the NOS1 gene. It produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In the brain and peripheral nervous system, NO displays many properties of a neurotransmitter.

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System and Oncology which include indications Dementia, Dyskinesia, Brain Injury, Melanoma, Migraine, Musculoskeletal Pain, Neuro Muscular Disorders, Neurodegenerative Diseases, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD) and Visceral Pain.

The latest report Nitric Oxide Synthase Brain - Pipeline Review, H1 2017, outlays comprehensive information on the Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

  • The report reviews Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)targeted therapeutics and enlists all their major and minor projects

  • The report assesses Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39)development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Pipeline Review, H1 2017

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Overview
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Companies Involved in Therapeutics Development
Eli Lilly and Company
Neurophyxia BV
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Drug Profiles
2-Iminobiotin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-462 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-613 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NXN-677 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Dormant Products
Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC 1.14.13.39) - Product Development Milestones
Featured News & Press Releases
Aug 31, 2015: Formulation patent granted in US, China, Australia and New Zealand
Jul 31, 2015: Neurophyxia Provides Update on Phase II study of 2-IB
Sep 30, 2014: Neurophyxia Provides Update on Phase II Clinical Study of 2-Iminobiotin
Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder
Feb 29, 2012: Neurophyxia Provides Update on 2-Iminobiotin
Jun 30, 2011: Neurophyxia Announces Completion of Phase I Study
Jun 30, 2010: Neurophyxia Provides Update on Cinical Study of 2-Iminobiotin
Jan 31, 2010: Neurophyxia Receives Orphan Drug Designation in Europe for 2-IB
Feb 28, 2009: Neurophyxia Receives Orphan Drug Designation from FDA for 2-Iminobiotin
Sep 30, 2008: Neurophyxia Provides Update on Pre-Cinical Study of 2-Iminobiotin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Eli Lilly and Company, H1 2017
Pipeline by Neurophyxia BV, H1 2017
Dormant Projects, H1 2017

List of Figures

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
  • Global Anti-Fungal Agents Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Anti-Fungal Agents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Anti-Fungal Agents for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japa......
  • Global Smoking Cessation and Nicotine De-Addiction Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Smoking Cessation and Nicotine De-Addiction market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Smoking Cessation and Nicotine De-Addiction for these regions, from 2012 to 2022 (forecast), covering - United S......
  • Global Protein Phosphatase 2A Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Protein Phosphatase 2A market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Protein Phosphatase 2A in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Chin......
  • Global Ectonucleotide Pyrophosphatase Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 108
    In this report, the global Ectonucleotide Pyrophosphatase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Ectonucleotide Pyrophosphatase in these regions, from 2012 to 2022 (forecast), covering - North America - Euro......
  • Global Meningioma Drug Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 115
    In this report, the global Meningioma Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Meningioma Drug in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Jap......
  • Global Gallbladder Cancer Treatment Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Gallbladder Cancer Treatment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gallbladder Cancer Treatment in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • Global Retinal Vein Occlusion Therapeutics Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Retinal Vein Occlusion Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Retinal Vein Occlusion Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America......
  • Global Urinary Tract Infection (UTI) Drugs Sales Market Report 2017
    Published: 11-Dec-2017        Price: US 4000 Onwards        Pages: 108
    In this report, the global Urinary Tract Infection (UTI) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Urinary Tract Infection (UTI) Drugs for these regions, from 2012 to 2022 (forecast), covering - United States - C......
  • Global Dual Specificity Protein Kinase TTK Market Research Report 2017
    Published: 11-Dec-2017        Price: US 2900 Onwards        Pages: 109
    In this report, the global Dual Specificity Protein Kinase TTK market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Dual Specificity Protein Kinase TTK in these regions, from 2012 to 2022 (forecast), covering - North America......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs